Q-omics provides the consensus-scored GJB5 profile across patient tissues and cancer cell-line models. GJB5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, GJB5 is differentially expressed in 14, with the highest sampling consensus in LUSC. Additionally, GJB5 RNA expression shows 14,909 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight PAAD, LUSC, and ESCA as cancer lineages where GJB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GJB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GJB5 survival associations across molecular data types. GJB5 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GJB5 RNA expression–survival associations across cancer types. High GJB5 expression shows unfavorable associations in PAAD, KICH, BRCA, ACC, SKCM and LUAD. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for GJB5 RNA expression.
This table summarizes GJB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GJB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GJB5 shows lower tumor expression in BRCA and higher tumor expression in LUSC, HNSC, COAD, LUAD and KIRP. The LUSC box plot shows higher GJB5 RNA expression in tumor versus normal tissue (log2 FC = +4.975, t-test p < 0.001).
This table shows molecular features associated with GJB5 in patient tissues and cancer cell lines. In patient samples, GJB5 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GJB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
